期刊文献+

I^-/Fe^(3+)体系查尔酮和β-烯胺酮[3+2]反应研究

The [3+2] reaction of chalcone and β-methionone in I^-/Fe^(3+) system
下载PDF
导出
摘要 二氢吡咯作为五元含氮杂环的常见的一类简单架构,是一类非常重要的化合物,表现出很高的生物活性.研究了在氯化铁和碘化锌引发条件下,查尔酮和β-烯胺在二氯乙烷作溶剂下发生加成/环合反应,合成了多取代的2,3-二氢吡咯类化合物.此方法采用常见的底物和温和的反应条件,为合成功能化二氢吡咯化合物提供了方便的路径.筛选了该反应的条件为以碳酸钾为碱,在碘化锌和氯化铁存在下,以10%~54%的收率得到2,3-二氢吡咯类化合物衍生物,并通过底物的拓展验证了反应的适用性,共合成了16个化合物. Dihydropyrrole and its derivatives are a class of important pentatomic heterocyclic compounds.Because of the high biological activities these molecules present and thus have been widely used.A tandem Miachael/cyclization/elimination sequence was studied for the formation of a series of 16 polysubstituted 2,3-dihydropyrroles from chalcones andβ-enamines.The results showed that the optimal parameters were as follows:a mixture of chalcones,1.2 equivalentβ-enamines,1.5 equivalent ZnI2,1.5 equivalent FeCl3 and 1 equivalent K2 CO3 together with 2 mL DCE under 80 ℃ and obtained corresponding products in 10%~54% yields.
作者 高建荣 辛明 李郁锦 GAO Jianrong,XIN Ming,LI Yujin(State Key Laboratory Breeding Base of Green Chemistry-Synthesis Technology,Zhejiang University of Technology,Hangzhou 310014,Chin)
出处 《浙江工业大学学报》 CAS 北大核心 2018年第4期435-440,共6页 Journal of Zhejiang University of Technology
基金 国家自然科学基金资助项目(21176223) 浙江省自然科学基金资助项目(LY13B020016)
关键词 二氢吡咯 查尔酮 串连反应 环合反应 dihydropyrrole chalcones tandem reaction cyclization
  • 相关文献

参考文献3

二级参考文献49

  • 1徐宝财,辛秀兰,胡燕霞,肖阳,于凉云.(S)-α-乙基-2-氧代-1-吡咯烷基乙酰胺的合成工艺进展[J].精细与专用化学品,2004,12(24):15-17. 被引量:2
  • 2穆振义.吡咯并吡咯二酮(DPP)类颜料及苯腈取代衍生物(二)[J].上海染料,2004,32(6):20-26. 被引量:3
  • 3王能强,吴坚平,邹小明,王普,杨立荣.α-氯丙酸脱卤酶发酵培养基的响应面法优化[J].化工学报,2007,58(1):176-180. 被引量:7
  • 4ISOHERRANEN N, ROEDER M, SOBACK S, et al. Enan- tioselective analysis of levetiracetam and its enantionmer R-aethyl-2-O-1-pyrrolidineacetamide using gas chromatography and ion trap mass spectrometric detection[J]. Journal of Chromatography B, 2000,745 (2) : 325-332.
  • 5WU T, CHEN C C, CHEN T C, et al. Clinical efficacy and cognitive and neuropsychological effects of levetiracetam in epilepsy: an open-label multicenter study[J]. Epilepsy & Behavior,2009,16(3):468-474.
  • 6BOSCHI F, CAMPS P, FRANCHINI C F, et al. A synthesis of levetiraeetam based on (S)-N-phenylpantolaetarn as a ehiral auxiliary[J]. Tetrahedron Asymmetry, 2005,16 (22) : 3739- 3745.
  • 7GIDAL B E, BALTES E, OTOUL C, et al. Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trial [J]. Epilepsy Research, 2005,64 (1) : 1-11.
  • 8SNOECK E, JACQMIN P, SARGENTINI-MAIER M L, et al. Modeling and simulation of intravenous levetiracetam pharmacokinetic profiles in children to evaluate dose adaptation rules[J]. Epilepsy Research,2007,76(2) : 140-147.
  • 9DUDRA-JASTRZEBSKA M, ADRES-MACH M M, SIELS- KI M, et al. Pharmaeodynamie and pharmacokinetic interaction profiles of levetiracetam in combination with gabapentin, tiagabine and vigabatrin in the mouse pentylenetetrazote-induced seizure model an isobolographic analysis[J]. European Journal of Pharmacology, 2009,605 (1) : 87-94.
  • 10PATSALOS P N. Pharmacokinetic profile of levetiracetam: toward ideal characteristics[J]. Pharmeology & Therapeutics, 2000,85(2) :77-85.

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部